NDAORALTABLET, CHEWABLE2 Generics Approved
Approved
Jan 2017
Lifecycle
Peak
Competitive Pressure
60/100
Clinical Trials
18
Data completeness
4/8 — Partial
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Vyvanse (lisdexamfetamine dimesylate) is an oral CNS stimulant indicated for attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder. It is a prodrug that is converted in the body to dexamphetamine, providing sustained therapeutic effects with a lower abuse potential compared to immediate-release formulations.
$139MPart D
PeakPeak lifecycle status with $139M in Part D spending indicates mature commercial infrastructure and stable demand, supporting mid-to-senior level commercial and medical affairs team expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder
Started Sep 2025
105 enrolled
Obesity and OverweightBinge Eating Disorder
Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
Started Jun 2019
150 enrolled
Binge-eating Disorder
Open Label Extension in Adults With Binge Eating Disorder (BED)
Started Aug 2012
604 enrolled
Binge Eating Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
Started Apr 2012
464 enrolled
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
Started Apr 2012
549 enrolled
Attention-deficit/Hyperactivity Disorder
Worked on VYVANSE at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.